Bifidobacterium breve rrjk1316 and use thereof

Abstract

The application belongs to the technical field of microorganisms, and particularly relates to a Bifidobacterium breve RRJK1316 capable of promoting digestion and application thereof. Bifidobacterium breve The Bifidobacterium breve is named as Bifidobacterium breve (RRJK1316), is preserved in the Guangdong Microbial Culture Collection Center, and has a preservation number of GDMCC No. 64764. The strain has strong acid and bile salt resistance, can effectively resist the influence of gastric juice, and can maintain high activity after passing through the digestive tract. The strain has strong digestion promotion function, and the digestion promotion function is better than that of domperidone 75.0 mu g / mL when the concentration of live bacteria is 6.00*10 8 CFU / mL. Meanwhile, the strain has the function of relieving lactose intolerance, and the beta-galactoside enzyme activity reaches 0.793 U / mL.

Description

Technical Field

[0001] The present invention belongs to the technical field of microorganisms, and particularly relates to Bifidobacterium breve RRJK1316 capable of promoting digestion and applications thereof. Background Art

[0002] With the accelerated pace of modern life, changes in dietary structure (such as high-fat, high-sugar, low-fiber diets), and the overuse of antibiotics, digestive health issues are becoming increasingly prominent. Specifically, a long-term high-fat diet promotes bile acid secretion, alters intestinal pH, and leads to a decrease in the number of beneficial bacteria such as Bifidobacterium. Meanwhile, the use of antibiotics can indiscriminately kill beneficial bacteria in the intestines, causing dysbiosis and subsequently leading to diarrhea, constipation, or intestinal inflammation. Common digestive dysfunctions such as indigestion, bloating, constipation, diarrhea, and intestinal flora imbalance not only affect quality of life but can also lead to more serious metabolic diseases (such as obesity and diabetes) and immune system disorders. Therefore, the development of safe and effective probiotics to improve digestive function has significant market value and health implications.

[0003] Currently, commercially available probiotic products primarily include lactic acid bacteria and bifidobacteria, but different strains have varying functions. Some strains have low survival rates in gastric acid and bile, making it difficult for them to effectively colonize the intestines. Furthermore, many probiotic products have limited effectiveness in improving specific digestive issues. Summary of the Invention

[0004] To solve the above problems, the technical solution of the present invention is as follows: a short bifidobacterium capable of promoting digestion, the short bifidobacterium is named as short bifidobacterium ( Bifidobacterium breve )RRJK1316, deposited in the Guangdong Provincial Microbiological Culture Collection Center GDMCC, with the deposit number GDMCC No.64764 and the deposit date June 17, 2024.

[0005] A bacterial agent comprising the above-mentioned Bifidobacterium breve capable of promoting digestion.

[0006] A postbiotic, wherein the raw materials of the postbiotic include the culture, inactivated bacteria, fermentation products and / or metabolites of the above-mentioned Bifidobacterium breve capable of promoting digestion.

[0007] The above-mentioned postbiotics further include at least one regulatory acceptable excipient.

[0008] The above-mentioned culture products include culture fluid, culture fluid supernatant, crushed product, concentrated product, sterilized product, gelatinized product or dried product.

[0009] The above-mentioned culture is a culture solution or a dried product, and the dried product is a powder obtained by spray-drying the culture solution.

[0010] Use of the aforementioned Bifidobacterium breve capable of promoting digestion, the aforementioned bacterial agent or the aforementioned postbiotic in the preparation of a product that helps promote digestion.

[0011] A product that helps promote digestion, comprising the aforementioned Bifidobacterium breve capable of promoting digestion, the aforementioned bacterial agent, or the aforementioned postbiotic.

[0012] The above-mentioned product includes medicine or food.

[0013] The above-mentioned products include reconstituted milk, sterilized milk, fermented milk, condensed milk, cream, light cream, anhydrous butter, concentrated milk, compound protein drinks, coffee drinks, plant-based drinks, flavored drinks, sports drinks, nutrient drinks, energy drinks, electrolyte drinks, whole milk powder, skimmed milk powder, partially skimmed milk powder, reconstituted milk powder, whey powder, cheese, processed cheese, ice cream, slush, popsicles, edible ice, sweetened ice or ice cream.

[0014] The above-mentioned product further comprises at least one regulatory acceptable auxiliary material or pharmaceutically acceptable excipient.

[0015] The above-mentioned product, the food includes a nutrient supplement.

[0016] The above-mentioned product, the dosage form of the food includes tablets, capsules, soft capsules, granules, pills, gel candies, powders, oral liquids or drops.

[0017] The above-mentioned product, the medicine can be a pharmaceutical composition.

[0018] The Bifidobacterium breve of the present invention ( Bifidobacterium breve )RRJK1316 has a strong digestive function, 6.00×10 8 The digestive function of a viable bacterial concentration of 75.0 μg / mL is superior to that of domperidone at a concentration of 75.0 μg / mL. It also alleviates lactose intolerance, with a β-galactosidase activity of 0.793 U / mL.

[0019] Bifidobacterium breve, named Bifidobacterium breve ( Bifidobacterium breve )RRJK1316 was deposited in the "Guangdong Provincial Microbial Culture Collection Center" on June 17, 2024, with the deposit number GDMCC No. 64764, and the deposit address is: 5th Floor, Building 59, No. 100 Xianlie Middle Road, Guangzhou. BRIEF DESCRIPTION OF THE DRAWINGS

[0020] 图1 This is the colony morphology of Bifidobacterium breve RRJK1316.

[0021] 图2 These are typical graphs of zebrafish intestinal fluorescence intensity, where (a) is the normal control group, (b) is Bifidobacterium breve RRJK1316 1500 μg / mL, (c) is the model control group, (d) is Bifidobacterium breve RRJK1316 3000 μg / mL, (e) is domperidone 75.0 μg / mL, and (f) is Bifidobacterium breve RRJK1316 6000 μg / mL.

[0022] Bifidobacterium breve ( Bifidobacterium breve )RRJK1316, deposited in the Guangdong Provincial Microbiological Culture Collection Center GDMCC, with the deposit number GDMCC No.64764 and the deposit date June 17, 2024. DETAILED DESCRIPTION

[0023] Example 1 Screening and identification of Bifidobacterium breve RRJK1316

[0024] 1. Screening of Bifidobacterium breve RRJK1316.

[0025] (1) Separation.

[0026] Take 0.5mL of infant feces sample and add it to 4.5mL of MRS diluent and dilute it 10-fold to 10 -6 , take appropriate dilution gradients and spread them on MRS solid culture medium plates, and culture them in anaerobic jars at 37℃ for 48h.

[0027] (2) Purification.

[0028] Pick a single colony with typical characteristics of the target strain, which is milky white, round, convex, smooth surface, neat edges, and about 3 mm in diameter, and perform streak purification culture on modified MRS medium until the characteristics of the colonies in the streak plate are consistent.

[0029] (3) Microscopic examination.

[0030] From each purified plate, select two single colonies for smearing and Gram staining. Observe their color and shape under a microscope to determine if the colonies are pure cultures. If the microscopic observation results are consistent, the resulting pure culture (plate colonies) is designated as a suspected strain and the corresponding plate number is assigned for identification. If the microscopic observation results are inconsistent, continue with the above steps.

[0031] The improved MRS medium includes: 10 g / L peptone, 3 g / L beef powder, 4 g / L yeast extract, 2 g / L dipotassium hydrogen phosphate, 2 g / L citric acid, 5 g / L sodium acetate, 20 g / L glucose, 0.58 g / L magnesium sulfate heptahydrate, 0.25 g / L manganese sulfate tetrahydrate, 0.6 g / L Tween-80, 10 g / L calcium carbonate, 0.05 g (1% concentration in 5 mL), 10 mL / L (v / v) tomato juice, and 20 g / L agar powder. The pH is adjusted to 5.5 and sterilized at 115°C for 30 minutes.

[0032] 2. Identification of Bifidobacterium breve RRJK1316.

[0033] The isolated and purified pure culture was subjected to bacterial species identification, including Gram staining test, catalase test and 16SrDNA full sequence sequencing. The isolated strain was finally identified as a breve Bifidobacterium, which was named Bifidobacterium breve ( Bifidobacterium breve )RRJK1316 was deposited in the Guangdong Provincial Microbiological Culture Collection Center on June 17, 2024, with the deposit number GDMCC No.64764.

[0034] The above-mentioned Bifidobacterium breve ( Bifidobacterium breve Strain RRJK1316 is Gram-positive, with pleomorphic, rod-shaped cells that do not form spores. Its colonies are milky white, round, convex, with smooth surfaces and neat edges. Its physicochemical characteristics include catalase and oxidase negativity, and its ability to utilize ribose, lactose, raffinose, sorbitol, mannose, fructose, galactose, sucrose, maltose, trehalose, melibiose, and salicin. The 16S rDNA sequence is shown in SEQ ID NO: 1.

[0035] Example 2 Ability of Bifidobacterium breve RRJK1316 strain to resist adverse digestive tract environment

[0036] 1. Acid and bile salt resistance test of Bifidobacterium breve RRJK1316.

[0037] The composition of the culture medium used in the experiment is as follows:

[0038] MRS + L medium: yeast peptone 10 g / L, beef powder 3 g / L, yeast extract powder 10 g / L, potassium dihydrogen phosphate 2 g / L, citric acid monohydrate 2 g / L, sodium acetate 5 g / L, anhydrous glucose 20 g / L, magnesium sulfate 0.58 g / L, manganese sulfate 0.25 g / L, Tween 80 0.6 g / L, tomato juice 10 mL / L, L-cysteine ​​hydrochloride 1 g / L.

[0039] MRS + L solid medium: MRS + L medium, agar powder 12 g / L.

[0040] (1) Acid resistance test

[0041] The bacteria liquid passed three times was inoculated into MRS+L medium with pH 3.0 at an inoculation amount of 10%, and sampled after anaerobic culture at 39±0.5°C for 3h, and then diluted by 10 times with sterilized normal saline, and 1000 μL of bacteria liquid at an appropriate dilution degree was taken for viable count operation, twice repeated for each dilution degree, and then counted after anaerobic culture at 39±0.5°C on MRS+L solid medium for 48-72h.

[0042] The acid resistance test data index: the viable count measured by sampling after 3h of culture (denoted by N'); the viable count measured by sampling at 0h (denoted by N0), and the logarithmic ratio of acid-resistant viable count was calculated according to the following formula:

[0043] The acid resistance survival rate of the test strain (%) = lg cfu N' / lg cfu N0x100%;

[0044] Table 1 Acid resistance test data table of Bifidobacterium breve RRJK1316

[0045]

[0046] As shown in the above table, the survival rate of Bifidobacterium breve RRJK1316 strain was still 96.45% after 3h at pH 3.0, indicating that the strain could maintain high activity after the inhibition of gastric acid, thereby exerting its probiotic effect.

[0047] (2) Bile salt resistance test

[0048] The bacteria liquid passed three times was inoculated into 10 mL MRS+L liquid medium containing 0.3% and 0.5% bile salt, respectively, at an inoculation amount of 10%, and sampled after anaerobic tank culture at 39±0.5°C for 4h, and then diluted by 10 times with sterilized normal saline, and 1 mL of bacteria liquid at an appropriate dilution degree was taken for viable count operation, twice repeated for each dilution degree, and then counted after anaerobic tank culture at 39±0.5°C on MRS+L solid medium for 48-72h.

[0049] The bile salt resistance test data index: the viable count measured by sampling after 4h of culture (denoted by N'); the viable count measured by sampling at 0h (denoted by N0), and the logarithmic ratio of acid-resistant viable count was calculated according to the following formula:

[0050] The acid resistance survival rate of the test strain (%) = lg cfu N' / lg cfu N0x100%;

[0051] Table 2 Bile salt resistance test data table of Bifidobacterium breve RRJK1316

[0052]

[0053] As shown in Table 2, the survival rate of Bifidobacterium breve RRJK1316 strain increases with the increase of bile salt concentration. Under the treatment of 0.5% bile salt concentration, the survival rate can reach 100%.

[0054] Bifidobacterium breve RRJK1316 simulated gastric fluid test.

[0055] The bacterial suspension that had been passaged three times was shaken and evenly mixed. 10 mL of the bacterial suspension was centrifuged (5000 g, 10 min, 4°C) to obtain bacterial sludge, which was then rinsed twice with PBS buffer. The obtained bacterial sludge was resuspended in 10 mL of simulated gastric fluid and sampled after anaerobically digesting at 39±0.5°C for 3 h. A series of 10-fold gradient dilutions were performed with sterile saline. 1 mL of the bacterial suspension of the appropriate dilution was taken for mixed bacterial counting. Each dilution was repeated twice. The cells were cultured in an anaerobic jar at 39±0.5°C for 48-72 h before counting.

[0056] Simulated gastrointestinal fluid test data indicators:

[0057] Data indicators of the simulated gastric fluid test: the number of viable bacteria of the test strain in the third generation culture medium after three generations of activation (expressed as N); the number of viable bacteria measured by sampling and counting after 3 hours (expressed as N");

[0058] The survival rate of the test strain in the simulated gastric fluid test (%) = lgcfuN” / lgcfu N×100%.

[0059] Table 3. Data of simulated gastric fluid test of Bifidobacterium breve RRJK1316

[0060]

[0061] As shown in Table 3, the Bifidobacterium breve RRJK1316 strain has a strong survival ability in simulated gastric fluid. After 3 hours of treatment, the survival rate is as high as 100.0%. It stays in the stomach for a long time and still maintains high activity.

[0062] In summary, this shows that the strain has strong acid and bile salt resistance, and can effectively resist the influence of gastric juice, so that it can still maintain high activity after passing through the digestive tract.

[0063] Example 3: Digestive Efficacy Test of Bifidobacterium breve RRJK1316

[0064] 1. Maximum detectable concentration (MTC) determination.

[0065] Wild-type AB zebrafish, 3 days post-fertilization (dpf), were randomly selected and placed in culture dishes. All experimental groups, except the normal control group, were treated with water-soluble TNBS to establish a zebrafish indigestion model. After two days of treatment at 28°C, the TNBS was removed and the zebrafish were randomly distributed into 6-well plates, with 30 zebrafish treated per well (experimental group). Samples (concentrations shown in Table 4) were administered water-soluble, with a volume of 3 mL per well. A normal control group and a model control group were also set up. The zebrafish were treated at 28°C until 7 dpf, and the MTC of the samples in the model zebrafish was measured.

[0066] 2. Evaluation of digestive efficacy.

[0067] 3 dpf wild-type AB strain zebrafish were randomly selected and placed in culture dishes. Except for the normal control group, all other experimental groups were given TNBS in water to establish a zebrafish indigestion model. After 2 days of treatment at 28℃, TNBS was removed and Nile red was given in water as a fluorescent indicator of intestinal contents. After feeding, the zebrafish were randomly distributed into 6-well plates, and 30 zebrafish were treated in each well (experimental group). The samples were given in water (concentrations are shown in Table 5), and the positive control was domperidone at a concentration of 75.0 μg / mL. A normal control group and a model control group were also set up, with a volume of 3 mL per well. The cells were treated at 28℃ until 7 dpf. Ten zebrafish were randomly selected from each group and photographed under a fluorescence microscope and the images were saved. The data were analyzed and collected using NIS-Elements D 3.20 advanced image processing software. The fluorescence intensity of the zebrafish intestine was analyzed, and the statistical analysis results of this indicator were used to evaluate the efficacy of the sample in improving indigestion. The statistical results were expressed as mean ± SE. Statistical analysis was performed using SPSS26.0 software. p <0.05 indicated that the difference was statistically significant.

[0068] 3. Test results.

[0069] (1) MTC.

[0070] Under the experimental conditions, the digestive efficacy of Bifidobacterium breve RRJK1316 in zebrafish was 6000 μg / mL (see Table 4 for details).

[0071] Table 4 Results of the experimental study on the concentration of samples for promoting digestion (n = 30)

[0072]

[0073] (2) Evaluation of digestive efficacy.

[0074] Under the experimental conditions, Bifidobacterium breve RRJK1316 has a digestive effect, which is manifested by reducing the fluorescence intensity of the zebrafish gastrointestinal tract. 图2The fluorescence intensity of the B. breve RRJK1316 group was significantly lower than that of the model control group. When the concentration of B. breve RRJK1316 was 6000 μg / mL, i.e., 6.00 × 10 8 CFU / mL of viable bacteria, the fluorescence intensity of the zebrafish gastrointestinal tract was lower than that of metoclopramide, indicating that the digestion-promoting function at this concentration was better than that of metoclopramide at a concentration of 75.0 μg / mL.

[0075] Table 5 Results of sample digestion-promoting efficacy evaluation experiment (n = 10)

[0076]

[0077] Compared with the model control group, p <0.01, *** p <0.001.

[0078] Example 4 Efficacy test of B. breve RRJK1316 for relieving lactose intolerance

[0079] Principle of experiment and test strain.

[0080] O-nitrophenyl-β-D-galactopyranoside (ONPG) is a colorless compound that is easily soluble in water and can be used as a substrate for β-galactosidase. Under the catalysis of the enzyme, the glycosidic bond is broken to produce o-nitrophenol (ONP) and β-D-galactopyranose. The product ONP is a yellow substance, and as the substrate is decomposed, the color of the solution gradually deepens and has a maximum absorption peak at 420 nm. Therefore, the ONP production can be calculated by measuring the absorbance.

[0081] Table 6 Strain information of B. breve RRJK1316 and control strains

[0082]

[0083] 2. Culture medium and culture conditions

[0084] (1) Formulation of solid culture medium for B. breve.

[0085] Yeast extract 10 g / L, beef powder 3 g / L, yeast extract powder 10 g / L, potassium dihydrogen phosphate 2 g / L, citric acid 2 g / L, sodium acetate 5 g / L, anhydrous glucose 20 g / L, magnesium sulfate 0.58 g / L, manganese sulfate 0.25 g / L, Tween 80 0.6 g / L, tomato juice 10 mL / L, L-cysteine hydrochloride 1 g / L, pH to 6.5 ± 0.02, add agar powder 10 g / L after dispensing, sterilize at 115°C for 30 min.

[0086] (2) Formulation of B. breve-lac culture medium (liquid)

[0087] Yeast peptone 10 g / L, beef powder 3 g / L, yeast extract powder 10 g / L, potassium dihydrogen phosphate 2 g / L, citric acid monohydrate 2 g / L, sodium acetate 5 g / L, lactose 20 g / L, magnesium sulfate 0.58 g / L, manganese sulfate 0.25 g / L, Tween 80 0.6 g / L, tomato juice 10 mL / L, L-cysteine ​​hydrochloride 1 g / L, pH to 6.5 ± 0.02.

[0088] 3. Experimental reagents.

[0089] (1) Reaction buffer.

[0090] Weigh 8.8 g potassium dihydrogen phosphate (KH2PO4), 8.0 g potassium dihydrogen phosphate trihydrate (K2HPO4·3H2O), 0.25 g magnesium sulfate heptahydrate (MgSO4·7H2O) and 18.6 mg EDTA dihydrate (C 10 H 14 Dissolve N2Na2O8·2H2O) in 900 mL of water, transfer to a 1000 mL volumetric flask, dilute to volume with water and shake well. The pH value of the buffer solution should be between 6.50±0.05.

[0091] (2) o-Nitrophenol-β-D-galactoside (ONPG) substrate solution.

[0092] Dissolve 250.0 mg of o-nitrophenyl-β-D-galactopyranoside (ONPG) in approximately 80 mL of reaction buffer, then transfer to a 100 mL volumetric flask, dilute to volume with reaction buffer, and shake well. Prepare at least 2 hours before use.

[0093] (3) Sodium carbonate solution.

[0094] Dissolve 50 g of sodium carbonate (Na2CO3) and 37.2 g of EDTA dihydrate in approximately 900 mL of water to a volume of 1000 mL.

[0095] 4. Operation steps.

[0096] (1) Drawing of standard curve.

[0097] Weigh 0.1390 ​​g of o-nitrophenol (ONP) into a small beaker and dissolve it in 10 mL of 96% ethanol. Then transfer the solution into a 1 L volumetric flask, add water to the volume and shake well.

[0098] Use a pipette to transfer 2 mL, 4 mL, 6 mL, 8 mL, 10 mL, 12 mL, and 14 mL of solution from these solutions into different 100 mL volumetric flasks, add 25 mL of sodium carbonate solution, dilute to volume with buffer and shake well to prepare ONP of 0.02 mmol / L, 0.04 mmol / L, 0.06 mmol / L, 0.08 mmol / L, 0.10 mmol / L, 0.12 mmol / L, and 0.14 mmol / L, and use sterile water as a blank;

[0099] The amount of o-nitrophenol is used as the horizontal axis, and the absorbance of the dilution ΔOD is used as the horizontal axis. 420 Make a standard curve for the ordinate and derive the regression equation.

[0100] (2) Preparation of test strains.

[0101] (a) Primary culture: Remove the strain from the cryopreserved tube stored at -80°C, thaw by hand, mix thoroughly, and streak one loopful of the culture onto a solid plate containing Bifidobacterium breve. Incubate anaerobically at 39 ± 0.5°C for 48–72 h.

[0102] (b) Secondary culture: Pick a single colony into 5 mL of Bifidobacterium breve-lac liquid culture medium and culture at 39°C for 20 h ± 0.5, then cover with tin foil;

[0103] (c) Tertiary culture: Inoculate 5 mL of bacterial solution into 100 mL of Bifidobacterium breve-lac liquid culture medium, culture at 39°C for 16-20 h, and cover with tin foil.

[0104] (3) Determination of β-galactosidase activity (ONPG method).

[0105] Centrifuge 15 mL of the fermentation broth at 10,000 rpm at 4°C for 5 minutes. Collect the bacterial sludge and wash twice with an equal volume of 0.05 mol / L phosphate buffer (pH 6.8). Resuspend the cells in 3 mL of the aforementioned phosphate buffer and disrupt by ultrasonication. The conditions for disruption were: ultrasonic power 200 W, 1s / 9s on / off time, 60 cycles, and 4°C. Centrifuge at 10,000 rpm at 4°C for 20 minutes, and collect the supernatant to obtain the crude enzyme solution. Dilute the crude enzyme solution appropriately, then take 200 μL of the crude enzyme solution and preheat it in a water bath at 30°C for 5 minutes. Add 1 mL of ONPG solution, also preheated at 30°C for 5 minutes, shake well, and incubate in a water bath at 30°C for 10 minutes. Immediately add 400 μL of sodium carbonate solution to terminate the reaction. Measure the OD at 420 nm within 30 minutes.

[0106] Preparation of blank sample: the order of adding ONPG substrate and sodium carbonate solution was reversed, and the remaining steps were the same as those for sample preparation.

[0107] One enzyme activity unit (E) is defined as the amount of enzyme required to hydrolyze 1 μmol ONP per minute at 30°C. The enzyme activity E (U / mL) is calculated according to the following formula:

[0108] 4. Test results.

[0109] T Enzyme activity calculation formula:

[0110] In the formula: E is the enzyme activity in the fermentation broth, U / mL; f is the dilution multiple of the enzyme solution; V is the total volume of the reaction system, 1.6 mL; K is the slope of the standard curve, 3.1625; t is the reaction time, 10 min; V1 is the volume of the enzyme solution, 0.2 mL.

[0111] Table 7 RRJK1316 and control strain strain data for relieving lactose intolerance test

[0112]

[0113] As can be seen from the test data in Table 7, the β-galactosidase enzyme activity of Bifidobacterium breve RRJK1316 reaches 0.793 U / mL, which has a significant advantage compared with the control strain, which can reflect that Bifidobacterium breve RRJK1316 has a strong function of relieving lactose intolerance.

[0114] Example 5 Culture method of Bifidobacterium breve RRJK1316

[0115] The bacteria in the cryopreservation tube were transferred to 10 mL of the basic culture medium at an inoculation amount of 10%, and were statically cultured anaerobically at 37.0±0.5°C for 17.0±0.5h to obtain a bacterial suspension; the bacterial suspension was transferred to 100 mL of the basic culture medium at an inoculation amount of 5%, and was statically cultured anaerobically at 37.0±0.5°C for 17.0±0.5h; the bacterial suspension was inoculated into 300 mL of the optimized culture medium, and was statically cultured anaerobically at 37.0±0.5°C for 17.0±0.5h; the viable cell count of the bacterial suspension was determined to be 5.0×10 9 CFU / mL or more.

[0116] The basic culture medium comprises the following components:

[0117] 30 g / L of anhydrous glucose, 10 g / L of yeast extract powder, 15 g / L of yeast protein peptone, 2 g / L of citric acid, 5 g / L of sodium acetate, 2 g / L of potassium dihydrogen phosphate, 0.5 g / L of magnesium sulfate, 0.01 g / L of manganese sulfate, 0.6 g / L of Tween-80, and 5 g / L of soybean protein peptone, and the pH is adjusted to 7.20. The liquid loading amount is 80%.

[0118] The optimized culture medium comprises the following components:

[0119] Anhydrous glucose 30g / L, yeast extract powder 15g / L, yeast peptone 15g / L, citric acid 2g / L, sodium acetate 5g / L, potassium dihydrogen phosphate 2g / L, magnesium sulfate 0.5g / L, manganese sulfate 0.01g / L, Tween-80 0.6g / L, soy peptone 10g / L, adjust pH to 7.20. Filling volume 80%.

Claims

1. A use of Bifidobacterium breve that aids digestion in the preparation of a product that aids digestion, characterized in that: The Bifidobacterium breve is named Bifidobacterium breve ( Bifidobacterium breve )RRJK1316, deposited in Guangdong Provincial Microbial Culture Collection Center GDMCC, with the accession number GDMCC No.64764.

2. A bacterial agent, characterized in that The bacterial agent comprises the digestion-promoting Bifidobacterium breve according to claim 1.

3. Use of the bacterial agent according to claim 2 in the preparation of products that help promote digestion.

4. A product that aids digestion, characterized in that The product comprises the Bifidobacterium breve that aids digestion according to claim 1 or the bacterial agent according to claim 2.

5. The product according to claim 4, characterized in that The product includes a medicine or a food.

6. The product according to claim 5, characterized in that The product further comprises at least one regulatory excipient.

7. The product according to claim 5, characterized in that The food product includes a nutrient supplement.

8. The product according to claim 7, characterized in that The dosage form of the food is selected from tablets, capsules, granules, pills, gel candies, powders, oral liquids or drops.

Images